Breast cancer referrals to NHS Tayside genetic service: Are we meeting target timelines?
Breast Global Journal · 2023
DOI: 10.4103/bgj.bgj_19_23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Global Journal, 2023. Verfasst von Rebecca E Swan und 3 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben.
Abstract (Originalsprache)
A bstract Introduction: Mutations in BRCA1 and BRCA2 account for 5%–10% of all female breast cancers. Identifying these mutations at diagnosis can aid shared decision-making in the surgical and oncological setting. This study aims to assess the results of genetic testing at diagnosis and the time taken to receive results. Materials and Methods: A prospective database of all patients with newly diagnosed breast cancers who met the criteria and were referred for urgent genetic testing in National health service (NHS) (Tayside) between December 2017 and December 2020 was analyzed for results of genetic testing and time from referral to the result of genetic test. Results: Twelve of 116 patients (10.3%) had a mutation detected. Six had BRCA2 mutation (5.2%), four had BRCA1 mutation (3.4%), and two had PALB2 mutation (1.7%). Of patients with a mutation, six (50%) had triple-negative breast cancer aged 40 years, and two (16.7%) had breast cancer aged
Zitieren
APA
Swan, R. E., Pitcathley, M., Dunlop, J., & Choong, W. L. (2023). Breast cancer referrals to NHS Tayside genetic service: Are we meeting target timelines?. Breast Global Journal. https://doi.org/10.4103/bgj.bgj_19_23
Vancouver
Swan RE, Pitcathley M, Dunlop J, Choong WL. Breast cancer referrals to NHS Tayside genetic service: Are we meeting target timelines?. Breast Global Journal. 2023. doi:10.4103/bgj.bgj_19_23
BibTeX
@article{Swan2023,
author = {Swan, Rebecca E and Pitcathley, Madeleine and Dunlop, Jacqueline and Choong, Wen Ling},
title = {Breast cancer referrals to NHS Tayside genetic service: Are we meeting target timelines?},
journal = {Breast Global Journal},
year = {2023},
doi = {10.4103/bgj.bgj_19_23}
}
EUVIMED